Skip to main
PRME
PRME

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 36%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine Inc. is positioned for significant financial growth, with projections indicating that PM577 could generate risk-adjusted revenues of $980 million by 2035, rising from $32 million in 2030. The company is advancing its drug candidate PM577 for Wilson’s Disease, with expectations of an IND/CTA filing in the first half of 2026, suggesting a favorable commercial opportunity backed by strong preclinical data. Additionally, ongoing developments in gene editing and the potential positive readouts from clinical data in related technologies may further enhance investor interest and confidence in Prime Medicine's in vivo gene editing capabilities.

Bears say

The outlook for Prime Medicine's stock is negatively influenced by the potential challenges in regulatory approval for its gene editing therapies, which could lead to downward revisions of revenue projections. Additionally, recruitment difficulties for eligible patients in clinical programs may hinder the overall progress and success of its product pipeline. Finally, concerns regarding the affordability of Prime’s therapies in the market and safety risks associated with gene editing technologies further exacerbate the financial uncertainties facing the company.

PRME has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 14 analysts, PRME has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.